HOLLYWOOD, FL--(Marketwire - March 16, 2009) -
bioRASI, a full service, global Contract
Research Organization (CRO), announced today that they will participate in
the ASCPT 2009 Annual Meeting in Washington, D.C., on March 18th - 21st.
bioRASI will be exhibiting at booth # 138 and will showcase its full
service capabilities and unique global infrastructure that optimizes
Innovative Therapeutics, Generics and 505(b)(2) Programs.
"bioRASI has developed into a powerful full service global CRO that is
specifically focused on ANDA, 505(b)(2) NDA and the Translational Stage of
Innovative Therapeutics programs," said Dr. Boris Reznik, Chairman of
bioRASI. "Our Indian operations joined our very formidable North American
and Eastern European operations, and with our greater involvement in South
America, we now have a tremendous range of capabilities to help us optimize
the cost and time of clinical development programs for our sponsors."
Through its Innovative and Generics divisions, bioRASI leverages its
in-depth knowledge and global resources to provide a full range of services
to its sponsors, including program management, regulatory strategy design
and implementation, clinical development, analytical lab services, Part 11
compliant data management, data analysis and report writing.
bioRASI has leveraged its unique global access to strong PIs and special
patient populations to optimize translational clinical development
programs. Additionally, utilizing bioRASI's Phase I clinics and
bioanalytical laboratories, bioRASI has a rich history of completing
difficult to recruit and difficult to perform PK, BE and BA studies.
"As the Translational Clinical Development CRO, we can advance candidates
from IND enablement through Proof of Concept, Phase II trials,
expeditiously and cost effectively," said Gary W. Thompson, bioRASI's Vice
President of Business Development. "With access to thousands of subjects
in a number of categories, we have become leaders in difficult to recruit,
difficult to perform innovative therapeutics studies."
bioRASI is a Full Service Global CRO that collaborates with the leading
biotech and pharmaceutical companies in the clinical development of novel
and generic therapeutics. Specializing in Innovative, ANDA and 505(b)(2)
NDA programs, bioRASI facilitates obtaining FDA approvals by delivering
high quality regulatory and clinical strategies, solutions and services,
while saving their clients critical time. bioRASI services include program
management, regulatory, clinical, data management and analysis, compliance
and audit. bioRASI leverages its access to world renowned researchers and
facilities in the U.S., Europe and Asia, to achieve unparalleled
scientific, clinical and business results at significantly lower costs.
bioRASI is headquartered in Hollywood, FL and has regional offices, labs,
and clinics across the globe.